Werewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Werewolf Therapeutics (NASDAQ:HOWL) released its quarterly earnings results on Friday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02, FiscalAI reports.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock traded up $0.00 during mid-day trading on Friday, hitting $0.98. The company’s stock had a trading volume of 317,108 shares, compared to its average volume of 2,348,221. The company’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $0.70. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $1.20. The company has a market cap of $47.64 million, a PE ratio of -1.29 and a beta of 0.55.

Analyst Ratings Changes

HOWL has been the topic of several recent analyst reports. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics has an average rating of “Hold” and a consensus price target of $4.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.